quinine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4523	130-95-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: quinine bisulfate heptahydrate chinine qualaquin quinine quinine sulfate	An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. Molecular weight: 324.42 Formula: C20H24N2O2 CLOGP: 2.79 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 45.59 ALOGS: -2.99 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

quinine bisulfate heptahydrate
chinine
qualaquin
quinine
quinine sulfate

An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.

Molecular weight: 324.42
Formula: C20H24N2O2
CLOGP: 2.79
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 45.59
ALOGS: -2.99
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.50	g	O
1.50	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	111.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	12 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	71.07 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.80 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.30 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	11 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 12, 2005	FDA	MUTUAL PHARM CO INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	208.16	13.42	148	12379	59698	50532899
Labile blood pressure	152.82	13.42	42	12485	1618	50590979
Somatic symptom disorder	94.50	13.42	30	12497	1914	50590683
Sacroiliitis	89.83	13.42	31	12496	2566	50590031
Lipase increased	82.73	13.42	41	12486	8500	50584097
Hepatic ischaemia	78.05	13.42	20	12507	585	50592012
Haematemesis	74.90	13.42	59	12468	27666	50564931
Hepatorenal syndrome	72.90	13.42	24	12503	1719	50590878
Hepatic failure	59.17	13.42	55	12472	32228	50560369
Muscle relaxant therapy	55.47	13.42	12	12515	164	50592433
Coronary artery disease	53.24	13.42	50	12477	29676	50562921
Renal failure	48.19	13.42	91	12436	106542	50486055
Drug ineffective	46.24	13.42	83	12444	819250	49773347
Coagulopathy	45.92	13.42	37	12490	17907	50574690
Hyponatraemia	43.38	13.42	82	12445	96057	50496540
Thrombotic microangiopathy	43.19	13.42	27	12500	8764	50583833
Drug hypersensitivity	41.14	13.42	146	12381	250864	50341733
Electrocardiogram QT prolonged	40.86	13.42	57	12470	51829	50540768
Mood altered	40.69	13.42	30	12497	12743	50579854
Hypovolaemia	38.94	13.42	26	12501	9439	50583158
Duodenal ulcer	38.92	13.42	23	12504	6752	50585845
Toxicity to various agents	38.66	13.42	128	12399	212371	50380226
Fear of eating	37.86	13.42	10	12517	330	50592267
Gastrointestinal haemorrhage	33.63	13.42	63	12464	73258	50519339
Off label use	33.53	13.42	41	12486	474385	50118212
Post procedural haemorrhage	32.41	13.42	21	12506	7249	50585348
Product dose omission issue	31.85	13.42	4	12523	183834	50408763
Coronary artery bypass	31.45	13.42	14	12513	2279	50590318
Drug intolerance	31.01	13.42	8	12519	219096	50373501
Cognitive disorder	29.68	13.42	45	12482	44078	50548519
Retinal toxicity	29.14	13.42	11	12516	1177	50591420
Infusion related reaction	28.63	13.42	4	12523	169553	50423044
Pancreatitis	28.01	13.42	43	12484	42571	50550026
Cinchonism	26.98	13.42	4	12523	3	50592594
Rhabdomyolysis	26.53	13.42	40	12487	38987	50553610
Swollen tongue	26.43	13.42	34	12493	28596	50564001
Fatigue	26.20	13.42	89	12438	707512	49885085
Blood sodium decreased	25.90	13.42	29	12498	21118	50571479
Rheumatoid arthritis	25.75	13.42	9	12518	202541	50390056
Purpura senile	25.03	13.42	8	12519	521	50592076
Vestibular disorder	24.92	13.42	10	12517	1259	50591338
Tarsal tunnel syndrome	24.89	13.42	8	12519	531	50592066
Vascular injury	24.86	13.42	9	12518	856	50591741
Myocardial ischaemia	23.65	13.42	21	12506	11592	50581005
Oral cavity fistula	23.50	13.42	8	12519	635	50591962
Salivary gland enlargement	23.47	13.42	7	12520	362	50592235
Optic ischaemic neuropathy	23.44	13.42	9	12518	1008	50591589
Product use issue	22.04	13.42	5	12522	149470	50443127
Hiccups	21.89	13.42	10	12517	1729	50590868
Exostosis of jaw	21.86	13.42	9	12518	1210	50591387
Cerebral artery occlusion	21.23	13.42	8	12519	852	50591745
Muscle necrosis	21.21	13.42	7	12520	505	50592092
Eczema asteatotic	21.16	13.42	6	12521	259	50592338
Abdominal discomfort	20.99	13.42	16	12511	231625	50360972
Synovitis	20.72	13.42	3	12524	123862	50468735
Acute kidney injury	20.62	13.42	111	12416	227947	50364650
Exposed bone in jaw	20.11	13.42	11	12516	2789	50589808
Resorption bone increased	19.97	13.42	8	12519	1003	50591594
Fibromyalgia	19.81	13.42	38	12489	44940	50547657
Left ventricular dysfunction	19.43	13.42	18	12509	10488	50582109
Haemolytic uraemic syndrome	19.15	13.42	10	12517	2309	50590288
Abdominal rigidity	18.97	13.42	9	12518	1695	50590902
Ulcer	18.66	13.42	24	12503	20176	50572421
Adrenal mass	18.23	13.42	7	12520	785	50591812
Hepatocellular injury	18.21	13.42	27	12500	25920	50566677
Nail infection	17.68	13.42	9	12518	1972	50590625
Hepatic enzyme increased	17.63	13.42	6	12521	137374	50455223
Fall	17.46	13.42	142	12385	334790	50257807
Discomfort	17.28	13.42	3	12524	108377	50484220
Pain	16.83	13.42	80	12447	578823	50013774
Myocardial infarction	16.47	13.42	54	12473	88973	50503624
Cerebrovascular accident	16.26	13.42	56	12471	94624	50497973
Injection site pain	15.80	13.42	4	12523	111020	50481577
Therapeutic product effect decreased	15.71	13.42	7	12520	136043	50456554
Hand deformity	15.49	13.42	3	12524	100196	50492401
Agitated depression	15.45	13.42	4	12523	122	50592475
Rectal haemorrhage	15.08	13.42	31	12496	38527	50554070
Gastritis	14.69	13.42	28	12499	32955	50559642
Hyperkalaemia	14.67	13.42	35	12492	48054	50544543
Sequestrectomy	14.55	13.42	6	12521	810	50591787
Sedation complication	14.28	13.42	14	12513	8752	50583845
Sinusitis	13.94	13.42	13	12514	170545	50422052
Vaginal discharge	13.82	13.42	11	12516	5229	50587368
Disseminated intravascular coagulation	13.74	13.42	19	12508	17116	50575481
Multiple organ dysfunction syndrome	13.63	13.42	35	12492	50302	50542295
Nephrogenic systemic fibrosis	13.42	13.42	10	12517	4312	50588285

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	1059.02	16.22	469	6709	79414	29487935
Toxicity to various agents	254.88	16.22	258	6920	173403	29393946
Poisoning	88.98	16.22	45	7133	9948	29557401
Exposure via ingestion	58.44	16.22	21	7157	1997	29565352
Intentional product misuse	54.96	16.22	54	7124	34607	29532742
Compartment syndrome	47.42	16.22	19	7159	2433	29564916
Electrocardiogram U wave present	42.09	16.22	7	7171	19	29567330
Atrioventricular block	36.12	16.22	22	7156	6960	29560389
Cinchonism	33.68	16.22	5	7173	4	29567345
Toxic neuropathy	31.33	16.22	9	7169	416	29566933
Mouth swelling	29.74	16.22	12	7166	1564	29565785
Hypomagnesaemia	29.14	16.22	28	7150	17440	29549909
Urine sodium decreased	28.82	16.22	7	7171	167	29567182
Agitated depression	26.76	16.22	7	7171	227	29567122
Lower respiratory tract infection	25.82	16.22	32	7146	26470	29540879
Nephrogenic systemic fibrosis	24.53	16.22	14	7164	3928	29563421
Drug ineffective	22.94	16.22	33	7145	363137	29204212
Cerebral malaria	21.97	16.22	3	7175	0	29567349
Unresponsive to stimuli	20.81	16.22	28	7150	25098	29542251
Infected skin ulcer	20.73	16.22	9	7169	1408	29565941
Confusional state	20.60	16.22	73	7105	127804	29439545
Alveolar proteinosis	20.05	16.22	6	7172	320	29567029
Increased bronchial secretion	19.78	16.22	9	7169	1572	29565777
Body mass index decreased	19.39	16.22	5	7173	153	29567196
Cutaneous extramedullary haemopoiesis	18.68	16.22	3	7175	6	29567343
Hypocalcaemia	18.61	16.22	24	7154	20641	29546708
Lethargy	18.60	16.22	33	7145	37547	29529802
Blood sodium decreased	17.99	16.22	20	7158	14747	29552602
Skin induration	17.54	16.22	9	7169	2045	29565304

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	1178.78	13.28	620	17270	131754	64349088
Toxicity to various agents	229.89	13.28	382	17508	363131	64117711
Thrombotic microangiopathy	170.27	13.28	86	17804	16569	64464273
Labile blood pressure	134.43	13.28	41	17849	2039	64478803
Somatic symptom disorder	92.30	13.28	30	17860	1838	64479004
Sacroiliitis	81.89	13.28	31	17859	2981	64477861
Poisoning	76.82	13.28	57	17833	21822	64459020
Hepatic ischaemia	65.42	13.28	20	17870	1002	64479840
Drug ineffective	65.00	13.28	83	17807	840164	63640678
Exposure via ingestion	61.12	13.28	29	17861	4873	64475969
Cinchonism	59.54	13.28	9	17881	7	64480835
Haematemesis	57.44	13.28	68	17822	46931	64433911
Hepatorenal syndrome	55.57	13.28	25	17865	3721	64477121
Muscle relaxant therapy	54.11	13.28	12	17878	164	64480678
Hyponatraemia	53.03	13.28	123	17767	148216	64332626
Microangiopathic haemolytic anaemia	51.94	13.28	18	17872	1344	64479498
Intentional product misuse	45.40	13.28	76	17814	72219	64408623
Off label use	45.30	13.28	66	17824	632740	63848102
Acute kidney injury	44.30	13.28	243	17647	448997	64031845
Agitated depression	42.85	13.28	11	17879	288	64480554
Product dose omission issue	42.42	13.28	3	17887	194744	64286098
Atrioventricular block	39.28	13.28	30	17860	11985	64468857
Compartment syndrome	35.08	13.28	19	17871	4213	64476629
Blood sodium decreased	34.93	13.28	42	17848	29440	64451402
Fear of eating	34.76	13.28	10	17880	405	64480437
Mood altered	33.75	13.28	31	17859	15948	64464894
Retinal toxicity	33.68	13.28	13	17877	1317	64479525
Rhabdomyolysis	32.68	13.28	76	17814	91650	64389192
Coagulopathy	32.27	13.28	42	17848	31878	64448964
Coronary artery disease	30.81	13.28	58	17832	60375	64420467
Swollen tongue	30.78	13.28	43	17847	34911	64445931
Hypovolaemia	30.70	13.28	29	17861	15457	64465385
Electrocardiogram U wave present	30.36	13.28	7	17883	115	64480727
Hepatic failure	29.28	13.28	54	17836	55340	64425502
Nephrogenic systemic fibrosis	29.25	13.28	19	17871	5873	64474969
Duodenal ulcer	28.55	13.28	27	17863	14408	64466434
Renal failure	27.95	13.28	112	17778	181576	64299266
Rheumatoid arthritis	27.45	13.28	6	17884	164288	64316554
Exposed bone in jaw	27.09	13.28	15	17875	3472	64477370
Electrocardiogram QT prolonged	26.32	13.28	64	17826	79384	64401458
Fatigue	26.16	13.28	113	17777	748617	63732225
Post procedural haemorrhage	26.03	13.28	24	17866	12407	64468435
Toxic neuropathy	24.59	13.28	9	17881	787	64480055
Cognitive disorder	24.59	13.28	50	17840	55037	64425805
Tarsal tunnel syndrome	24.50	13.28	8	17882	497	64480345
Purpura senile	24.41	13.28	8	17882	503	64480339
Hypocalcaemia	23.72	13.28	42	17848	41711	64439131
Fall	23.26	13.28	196	17694	416630	64064212
Hypomagnesaemia	23.06	13.28	39	17851	37337	64443505
Lethargy	22.49	13.28	57	17833	72537	64408305
Salivary gland enlargement	22.42	13.28	7	17883	376	64480466
Vascular injury	22.18	13.28	9	17881	1040	64479802
Infusion related reaction	22.05	13.28	9	17881	164458	64316384
Cerebral malaria	21.57	13.28	3	17887	0	64480842
Cardiovascular disorder	21.10	13.28	24	17866	15857	64464985
Exostosis of jaw	21.05	13.28	9	17881	1185	64479657
Confusional state	20.97	13.28	134	17756	261010	64219832
Gastrointestinal haemorrhage	20.68	13.28	82	17808	132230	64348612
Contraindicated product administered	20.03	13.28	3	17887	107826	64373016
Ulcer	19.82	13.28	28	17862	22962	64457880
Drug intolerance	19.78	13.28	14	17876	187978	64292864
Myocardial ischaemia	19.57	13.28	28	17862	23223	64457619
Unresponsive to stimuli	19.32	13.28	43	17847	50350	64430492
Hepatic enzyme increased	19.31	13.28	6	17884	129937	64350905
Product use issue	19.23	13.28	9	17881	151706	64329136
Fibromyalgia	19.09	13.28	35	17855	35696	64445146
Bradycardia	19.07	13.28	74	17816	118145	64362697
Liver function test abnormal	18.77	13.28	47	17843	59354	64421488
Injection site pain	18.74	13.28	4	17886	111404	64369438
Oral cavity fistula	18.53	13.28	7	17883	669	64480173
Lower respiratory tract infection	18.45	13.28	63	17827	94551	64386291
Cerebrovascular accident	18.18	13.28	81	17809	137502	64343340
Treatment failure	18.08	13.28	5	17885	116811	64364031
Resorption bone increased	17.98	13.28	8	17882	1160	64479682
Synovitis	17.86	13.28	3	17887	99087	64381755
Melaena	17.59	13.28	43	17847	53505	64427337
Plasmodium falciparum infection	17.45	13.28	4	17886	64	64480778
Blindness transient	17.36	13.28	12	17878	4110	64476732
Nail infection	17.31	13.28	9	17881	1838	64479004
Skin induration	17.22	13.28	12	17878	4163	64476679
Eczema asteatotic	17.08	13.28	6	17884	466	64480376
Optic ischaemic neuropathy	17.07	13.28	10	17880	2575	64478267
Cardiac arrest	16.93	13.28	86	17804	153978	64326864
Blindness	16.35	13.28	25	17865	21994	64458848
Product use in unapproved indication	16.27	13.28	15	17875	176603	64304239
Alveolar proteinosis	15.88	13.28	6	17884	574	64480268
Coronary artery bypass	15.75	13.28	13	17877	5802	64475040
Cerebral artery occlusion	15.53	13.28	8	17882	1603	64479239
Lip swelling	15.49	13.28	30	17860	31877	64448965
Vestibular disorder	15.49	13.28	9	17881	2284	64478558
Vaginal discharge	15.35	13.28	11	17879	3986	64476856
Mouth swelling	15.06	13.28	12	17878	5095	64475747
Respiratory arrest	14.77	13.28	40	17850	52945	64427897
Muscle necrosis	14.53	13.28	7	17883	1216	64479626
Therapeutic product effect decreased	14.38	13.28	7	17883	115344	64365498
Abdominal rigidity	14.36	13.28	9	17881	2618	64478224
Depressed level of consciousness	13.97	13.28	52	17838	81384	64399458
International normalised ratio increased	13.96	13.28	51	17839	79116	64401726
Myocardial infarction	13.86	13.28	86	17804	165735	64315107
Increased bronchial secretion	13.71	13.28	9	17881	2833	64478009
Rectal haemorrhage	13.70	13.28	43	17847	61774	64419068
Sequestrectomy	13.66	13.28	6	17884	843	64479999
Left ventricular dysfunction	13.66	13.28	20	17870	16934	64463908

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M09AA72	MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Quinine and derivatives
ATC	P01BC01	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Methanolquinolines
FDA EPC	N0000175482	Antimalarial
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000962	Antimalarials
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000981	Antiprotozoal Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D009125	Muscle Relaxants, Central
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:38068	antimalarials
CHEBI has role	CHEBI:51371	muscle relaxants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Falciparum malaria	indication	62676009	DOID:14067
Chloroquine Resistant Plasmodium Falciparum Malaria	indication
Babesiosis	off-label use	21061004	DOID:9643
Atrial flutter	contraindication	5370000
Torsades de pointes	contraindication	31722008
End stage renal disease	contraindication	46177005	DOID:784
Atrial fibrillation	contraindication	49436004	DOID:0060224
Neuromuscular block, function	contraindication	55394004
Black water fever	contraindication	56625005	DOID:14068
Acute nephropathy	contraindication	58574008
Optic neuritis	contraindication	66760008	DOID:1210
Thrombotic thrombocytopenic purpura	contraindication	78129009	DOID:10772
Myasthenia gravis	contraindication	91637004	DOID:437
Hemolytic uremic syndrome	contraindication	111407006	DOID:12554
Anemia due to enzyme deficiency	contraindication	111577008
Prolonged QT interval	contraindication	111975006
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.44	acidic
pKa2	8.02	Basic
pKa3	4.1	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN				WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Ki	4.92	CHEMBL
Hemoglobin subunit alpha	Secreted	P69905	HBA_HUMAN				WOMBAT-PK
Potassium voltage-gated channel subfamily B member 2	Ion channel	Q92953	KCNB2_HUMAN	BLOCKER	IC50	4.90	IUPHAR
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.29	CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5.36	CHEMBL
Equilibrative nucleoside transporter 4	Transporter	Q7RTT9	S29A4_HUMAN	INHIBITOR	Ki	4.57	IUPHAR

External reference:

ID	Source
D08460	KEGG_DRUG
6183-68-2	SECONDARY_CAS_RN
6119-70-6	SECONDARY_CAS_RN
4018620	VANDF
4019926	VANDF
CHEBI:15854	CHEBI
QI9	PDB_CHEM_ID
CHEMBL170	ChEMBL_ID
CHEMBL2359966	ChEMBL_ID
2510	IUPHAR_LIGAND_ID
DB00468	DRUGBANK_ID
A7V27PHC7A	UNII
3034034	PUBCHEM_CID
647128	RXNORM
5023	MMSL
5405	MMSL
84102	MMSL
d00366	MMSL
002934	NDDF
002935	NDDF
373497008	SNOMEDCT_US
47065008	SNOMEDCT_US
47857006	SNOMEDCT_US
D011803	MESH_DESCRIPTOR_UI
C0034417	UMLSCUI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3002	CAPSULE	324 mg	ORAL	ANDA	31 sections
Qualaquin	HUMAN PRESCRIPTION DRUG LABEL	1	13310-153	CAPSULE	324 mg	ORAL	NDA	32 sections
QUALAQUIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-595	CAPSULE	324 mg	ORAL	NDA	32 sections
Qualaquin	HUMAN PRESCRIPTION DRUG LABEL	1	49708-153	CAPSULE	324 mg	ORAL	NDA	32 sections
QUININE SULFATE	HUMAN PRESCRIPTION DRUG LABEL	1	50742-238	CAPSULE	324 mg	ORAL	ANDA	21 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	53489-700	CAPSULE	324 mg	ORAL	NDA authorized generic	32 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	65162-811	CAPSULE	324 mg	ORAL	ANDA	20 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	65162-811	CAPSULE	324 mg	ORAL	ANDA	20 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	68084-947	CAPSULE	324 mg	ORAL	NDA authorized generic	31 sections
QUININE SULFATE	HUMAN PRESCRIPTION DRUG LABEL	1	68180-560	CAPSULE	324 mg	ORAL	ANDA	20 sections